PEG-irinotecan is under clinical development by JenKem Technology and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect PEG-irinotecan’s likelihood of approval (LoA) and phase transition for Colorectal Cancer took place on 18 Nov 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
In addition, the same event on 18 Nov 2021 decreased PEG-irinotecan’s Phase Transition Success Rate (PTSR) for Esophageal Cancer, decreased PTSR for Gastric Cancer, and decreased PTSR for Pancreatic Cancer.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PEG-irinotecan Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
PEG-Irinotecan is under development for the treatment of small cell lung cancer, relapsed or refractory cancers such as breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, ovarian cancer and glioblastoma multiforme. Irinotecan targets topoisomerase I enzyme. The pegylated form enhances the permeability factor, tissue targeting property and enables prolonged action due to the polymeric nature. It is administered through parenteral and intravenous route.
JenKem Technology overview
JenKem Technology operates in pharmaceutical and healthcare industry. It is headquartered in China.
Quick View PEG-irinotecan LOA Data
|Highest Development Stage|